A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
NCT06456580Phase 3Active, not recruiting
- Lead sponsor
- Vor Biopharma (Industry)
- Enrollment
- 191 (actual)
- Start date
- 17 Jul 2024
- Primary completion
- Mar 2027 (estimated)
- Study completion
- 1 Jan 2029
- Last update posted
- 15 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- Telitacicept Biological
- Placebo Drug
Conditions and primary outcome
- Generalized Myasthenia Gravis
Primary outcome
Change from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) score at Week 24 (Week 24)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06456580.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06456580 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.